Back
  1. Home
  3. Detailled Reference
Request a copy
Paper published in a journal (Scientific congresses and symposiums)
Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
DI LEO, Angelo; JERUSALEM, Guy; PETRUZELKA, Lubos et al.
2012 • In Cancer Research. Supplement, 72 (24), p. 1-4
Peer reviewed
Permalink
https://hdl.handle.net/2268/156154
 

Files (2)Send toDetailsStatisticsBibliographySimilar publications

Files

Full Text
SABCS_2012_Abstract_Book[1].pdf
Publisher postprint (9.18 MB)
Request a copy
Annexes
San Antonio 27 nov[1].pdf
Publisher postprint (88.5 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to


Details


Disciplines :
Oncology
Author, co-author :
DI LEO, Angelo
JERUSALEM, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
PETRUZELKA, Lubos
TORRES, Roberto
BONDARENKO, Igor N.
KHASANOV, Rustem
VERHOEVEN, Didier
PEDRINI, José L.
SMIRNOVA, Iva
LICHINITSER, Mikhail R.
PENDERGRASS, Kelly
GARNETT, Sally
RUKAZENKOV, Yuri
MARTIN, Miguel
More authors (4 more) Less
Language :
English
Title :
Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
Publication date :
15 December 2012
Event name :
San Antonio Breast Cancer Symposium
Event organizer :
SABCS
Event place :
San Antonio, United States
Event date :
4-8 December, 2012
Audience :
International
Journal title :
Cancer Research. Supplement
ISSN :
0576-6656
Publisher :
University of Chicago Press, United States - Illinois
Volume :
72
Issue :
24
Pages :
S1-4
Peer reviewed :
Peer reviewed
Available on ORBi :
since 19 September 2013

Statistics

Number of views
66 (14 by ULiège)
Number of downloads
7 (7 by ULiège)
More statistics

Bibliography

Similar publications


Contact ORBi